Doheny Asset Management’s Forte Biosciences FBRX Stock Holding History

Doheny Asset Management’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-36	Closed	-$126K	–	101
2018 Q2	$126K	Sell	36 -4	-10%	-$14.6K	0.07%	98
2018 Q1	$177K	Buy	40 +9	+29%	+$41.7K	0.09%	101
2017 Q4	$120K	Sell	31 -12	-28%	-$47.9K	0.06%	105
2017 Q3	$202K	Sell	43 -420	-91%	-$1.87M	0.09%	106
2017 Q2	$2.09M	Buy	+463	New	+$2.6M	0.98%	27

Other funds holding FBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Doheny Asset Management's FBRX Position: Q3 2018 in Review

Doheny Asset Management sold out of Forte Biosciences (FBRX) in Q3 2018, closing a stake of 36 shares — an estimated $126K sold.

Doheny Asset Management first reported a position in FBRX in Q2 2017 and held it in 5 quarters. The position peaked at $2.09M in Q2 2017. 63 funds tracked by Wall St. Rank hold FBRX as of Q3 2018.

Doheny Asset Management reported no remaining Forte Biosciences position as of Q3 2018 after selling out during the quarter.
Doheny Asset Management sold 36 Forte Biosciences shares in Q3 2018, an estimated $126K.
Doheny Asset Management first reported a position in Forte Biosciences in Q2 2017 and held it in 5 quarters.
Doheny Asset Management's Forte Biosciences position peaked at $2.09M in Q2 2017.
63 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2018.

Based on Doheny Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.